Last reviewed · How we verify

Ureaplasma Urealyticum Infections — Treatment Landscape & Competitive Intelligence

Ureaplasma Urealyticum Infections (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ureaplasma Urealyticum Infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Minocycline Hydrochloride MINOCYCLINE Rempex Tetracycline-class Drug 1971-01-01
Minocyclin Minocyclin University of Southern California 30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Rempex · 1 drug in Ureaplasma Urealyticum Infections
  2. University of Southern California · 1 drug in Ureaplasma Urealyticum Infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ureaplasma Urealyticum Infections:

Cite this brief

Drug Landscape (2026). Ureaplasma Urealyticum Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ureaplasma-urealyticum-infections. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing